TFRC and glioma: Leveraging the binding affinity of the T7 peptide to the transferrin receptor (TfR) overexpressed on the BBB and glioma cells, this approach aims to facilitate targeted drug payload delivery to glioblastoma, with subsequent internalization and Cat B-mediated cleavage ensuring site-specific drug release within cancer cells [46,47].